| Autor: |
R P, Gale, T, Büchner, M J, Zhang, A, Heinecke, R E, Champlin, K A, Dicke, E, Gluckman, R A, Good, A, Gratwohl, R H, Herzig, A, Keating, J P, Klein, A M, Marmont, H G, Prentice, P A, Rowlings, K A, Sobocinski, B, Speck, R S, Weiner, M M, Horowitz |
| Rok vydání: |
1996 |
| Předmět: |
|
| Zdroj: |
Leukemia. 10(11) |
| ISSN: |
0887-6924 |
| Popis: |
There is controversy whether adults with acute myelogenous leukemia (AML) in first remission are best treated with chemotherapy or an HLA-identical sibling bone marrow transplant. We studied 1097 adults, 16-50 years old, with AML in first remission. Results of transplants from HLA-identical siblings reported to the International Bone Marrow Transplant Registry (IBMTR; n = 901) were compared with results of chemotherapy in comparable persons treated by the German AML Cooperative Group (GAMLCG; n = 196). Preliminary analyses identified subject- and disease-related variables differing between the cohorts and associated with treatment outcome within each cohort. We adjusted for these variables and differences in time-to-treatment in subsequent comparisons of treatment-related mortality, relapse, survival and leukemia-free survival (LFS). Five-year probability of treatment-related mortality was greater for transplants than chemotherapy (43% (95% confidence interval, 37-49%) vs 7% (3-11%); P0.0001). Five-year relapse probability was less for transplants than chemotherapy (24% (20-28%) vs 63% (55-71%); P0.0001). Five-year probability of survival was similar with transplants and chemotherapy (48% (43-53%) vs 42% (33-51%); P = 0.24). Five-year LFS probability was higher for transplants than chemotherapy (46% (42-50%) vs 35% (28-41%); P= 0.01). These data indicate that bone marrow transplants from HLA-identical siblings result in comparable survival but greater LFS than chemotherapy in adults with AML in first remission. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
